Fingolimod safety review
20 April 2012
The European Medicines Agency (EMA) has published its recommendations for the management of potential problems in people starting treatment with fingolimod (Gilenya). The recommendation says that doctors should not prescribe the drug to people with a history of cardiovascular disease, such as heart or blood pressure problems. People starting the drug should also be monitored before and for six hours after their first treatment.